Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491224 | 0.88 | SMN1; SMN2 (0.47) | HIF1ACA12CA1CA2CA9 | |
| SCHEMBL490843 | 0.88 | HSD17B2 (0.57) | ACHEALDH1A1NPSR1 | |
| SCHEMBL13194469 | 0.86 | HIF1A (0.45) | HIF1ACA12CA1CA2CA9 | |
| SCHEMBL137638 | 0.86 | ALDH1A1 (0.47) | HIF1ACA12CA1CA2CA9 | |
| SCHEMBL13194468 | 0.86 | HIF1A (0.45) | HIF1ACA12CA1CA2CA9 | |
| SCHEMBL490307 | 0.85 | PKM (0.48) | HIF1ACA12CA1CA2CA9 | |
| SCHEMBL5022505 | 0.85 | CYP2C19 (0.54) | HIF1ACA1CA2ACHEPTGS2 | |
| SCHEMBL31409463 | 0.85 | CYP2C19 (0.54) | HIF1ACA1CA2ACHEPTGS2 | |
| SCHEMBL31409467 | 0.85 | CYP2C19 (0.54) | HIF1ACA1CA2ACHEPTGS2 | |
| SCHEMBL31083332 | 0.85 | CYP2C19 (0.54) | HIF1ACA1CA2ACHEPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949966-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949966-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949966-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3099685-B1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | disclosed |
| CN-105899508-B | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2017-07-04 | — | — | CN | disclosed |
| EP-3099685-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9458153-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| CN-101203278-A | Ultraviolet protection | MERCK PATENT GMBH (DE) | 2008-06-18 | — | — | CN | disclosed |
| CN-101163659-A | Antioxidants | MERCK PATENT GMBH (DE) | 2008-04-16 | — | — | CN | disclosed |
| US-5098892-A | Angiotensin converting enzyme inhibitors as hypotensive agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-24 | — | — | US | disclosed |
| US-4822818-A | ANTIHYPERTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-18 | — | — | US | disclosed |
| US-4474692-A | L-Alanyl-N-(indan-2-yl)glycine, its esters and salts thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-10-02 | — | — | US | disclosed |
| EP-0051391-B1 | BICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-09-05 | — | — | EP | disclosed |
| EP-0057998-B1 | ALICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-08-08 | — | — | EP | disclosed |
| EP-0057998-A1 | Alicyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-08-18 | — | — | EP | disclosed |
| EP-0051391-A1 | Bicyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | HIF1A 478/4885CA12 3215/4885CA1 2392/4885 |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, DHX15 | HIF1A 1843/4885CA12 4685/4885CA1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.